
## Arndt-Christian MÃ<sup>1</sup>/<sub>4</sub>ller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5524958/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	On the probability of lymph node negativity in pNO-staged prostate cancer—aÂtheoretically derived rule of thumb for adjuvant needs. Strahlentherapie Und Onkologie, 2022, 198, 690-699.	1.0	1
2	Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases. Strahlentherapie Und Onkologie, 2022, 198, 683-689.	1.0	4
3	Prospective Image Quality and Lesion Assessment in the Setting of MR-Guided Radiation Therapy of Prostate Cancer on an MR-Linac at 1.5 T: A Comparison to a Standard 3 T MRI. Cancers, 2021, 13, 1533.	1.7	14
4	Radiotherapy in nodal oligorecurrent prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 575-580.	1.0	11
5	Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study. Frontiers in Oncology, 2021, 11, 705964.	1.3	22
6	<sup>68</sup> Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery. Acta Oncológica, 2020, 59, 149-156.	0.8	9
7	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	0.9	132
8	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2328-2338.	3.3	13
9	Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer. Acta Oncológica, 2020, 59, 911-917.	0.8	5
10	Prospective evaluation of probabilistic dose-escalated IMRT in prostate cancer. Radiology and Oncology, 2020, 55, 88-96.	0.6	2
11	Intention-to-Treat Analysis of <sup>68</sup> Ga-PSMA and <sup>11</sup> C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. Journal of Nuclear Medicine, 2019, 60, 1359-1365.	2.8	29
12	EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 2019, 30, 1697-1727.	0.6	96
13	Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. Radiotherapy and Oncology, 2018, 126, 257-262.	0.3	19
14	Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in more than 250 patients. Radiology and Oncology, 2016, 50, 329-336.	0.6	29
15	Nodal Clearance Rate and Long-Term Efficacy ofÂIndividualized Sentinel Node–Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 263-271.	0.4	6
16	Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial. Radiation Oncology, 2015, 10, 138.	1.2	8
17	Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer. BMC Cancer, 2013, 13, 27.	1.1	39
18	Toxicity and outcome of pelvic IMRT for node-positive prostate cancer. Strahlentherapie Und Onkologie, 2012, 188, 982-989.	1.0	19

#	Article	IF	CITATIONS
19	Importance of Bak for celecoxib-induced apoptosis. Biochemical Pharmacology, 2008, 76, 1082-1096.	2.0	12